Zydus Cadila receives approval for Zonisamide Capsules from US FDA

Cadila Healthcare Ltd has announced that the Company has received approval from the US FDA to market Zonisamide Capsules in different strengths of 25 mg, 50 mg and 100 mg. The drug falls in the anti-epileptic segment. The branded sales of Zonisamide Capsules in the US market was estimated at USD 178 mn in 2005 as per IMS. The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc.

This marks the l7th ANDA approval for the group since the commencement of filing process in FY 2003-04. So far the group has filed 41 ANDAs and 45 DMFs.

Source : Equity Bulls

Keywords